Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Post by threefiftynineon May 29, 2020 6:05pm

134 Views

Post# 31090243

----MPARTNERS-----

Brought the share price down to .075 to substantiate the .085 pp. MPARTNERS brought the share price back up again once again to give respectability to the PP going forward. Hopefully the insiders and especially the CEO find their wallet and spend a dime . This company will do nothing based on cancer testing . Covid19 is their only chance at financial success if PHASE1 comes up to the plate. If indeed they do step up to the plate cancer testing will take care of itself with the added exposure. Phase1 is a .40 cent stock ---no PHASE1 it will linger for years at the very low teens max.

Bullboard Posts

Morning Market Outlook for Nov. 7, 2024